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Abstract: The objectives in treating angina are relief of pain and prevention of disease 
  progression through risk reduction. Mechanisms, indications, clinical forms, doses, and 
side effects of the traditional antianginal agents – nitrates, β-blockers, and calcium channel 
  blockers – are reviewed. A number of patients have contraindications or remain unrelieved from 
anginal discomfort with these drugs. Among newer alternatives, ranolazine, recently approved 
in the United States, indirectly prevents the intracellular calcium overload involved in cardiac 
ischemia and is a welcome addition to available treatments. None, however, are disease-modifying 
agents. Two options for refractory angina, enhanced external counterpulsation and spinal cord 
stimulation (SCS), are presented in detail. They are both well-studied and are effective means 
of treating at least some patients with this perplexing form of angina. Traditional modifiable 
risk factors for coronary artery disease (CAD) – smoking, hypertension, dyslipidemia,   diabetes, 
and obesity – account for most of the population-attributable risk. Individual therapy of high-
risk patients differs from population-wide efforts to prevent risk factors from appearing or 
reducing their severity, in order to lower the national burden of disease. Current American 
College of Cardiology/American Heart Association guidelines to lower risk in patients with 
chronic angina are reviewed. The Clinical Outcomes Utilizing Revascularization and Aggressive 
Drug Evaluation (COURAGE) trial showed that in patients with stable angina, optimal medical 
therapy alone and percutaneous coronary intervention (PCI) with medical therapy were equal in 
preventing myocardial infarction and death. The integration of COURAGE results into current 
practice is discussed. For patients who are unstable, with very high risk, with left main coronary 
artery lesions, in whom medical therapy fails, and in those with acute coronary syndromes, 
PCI is indicated. Asymptomatic patients with CAD and those with stable angina may defer 
intervention without additional risk to see if they will improve on optimum medical therapy. 
For many patients, coronary artery bypass surgery offers the best opportunity for relieving angina, 
reducing the need for additional revascularization procedures and improving survival. Optimal 
medical therapy, percutaneous coronary intervention, and surgery are not competing therapies, 
but are complementary and form a continuum, each filling an important evidence-based need 
in modern comprehensive management.
Keywords: coronary artery disease, ischemic heart disease, myocardial oxygen balance, 
  cardiovascular risk reduction, acute coronary syndrome, COURAGE study, percutaneous 
  coronary intervention, revascularization, nitrates, β-blockers, calcium channel blockers, 
  ranolazine, refractory angina, prevention of heart disease, coronary artery bypass surgery, 
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Introduction
The goals in treating patients with chronic stable angina 
are (1) to relieve symptoms, (2) to prevent progression of 
the atherosclerotic process and reduce risk of myocardial 
infarction (MI) or sudden cardiac death, and (3) to control 
complicating factors which trigger or worsen ischemia. In 
the first of this 2 part series, the definition, clinical types 
of angina, differential diagnosis, risk stratification, and 
prognostication using exercise testing and imaging were 
addressed, with mention of gender disparities.1 In this second 
part, anti-ischemic therapy, newer agents, risk reduction, and 
revascularization are discussed.
Although sometimes difficult, the practitioner should impress 
upon the patient that no pill or surgical procedure will completely 
reverse the problem, but lifestyle changes will influence the 
course of the disease in the most fundamental way and are 
preferred. Lifestyle therapy is efficacious, widely available, 
innocuous, and an inexpensive form of management of angina 
and coronary artery disease (CAD), but is underused and unsup-
ported. Amply proven potential for reducing cardiovascular risk 
has not been realized.2 Reasons for its near-universal neglect are 
complex and only partially appreciated, but remain unsolved 
despite widespread praise for its value.3 The disconnection 
occurs between the oratory and effective implementation of 
lifestyle changes by patients – from counseling and contract 
to behavior change. The complete physician will use the first 
available opportunity to enlist the patient as a partner in initiating 
and continuing all lifestyle changes that will contribute to risk 
factor reduction and a training effect of exercise.
Antianginal therapy
Anti-ischemic therapy includes the use of 3 traditional 
antianginal agents: nitrates, β-blockers, and calcium chan-
nel blockers (CCBs). Traditional agents lower anginal 
symptoms and prolong exercise duration and/or time to 
ST-segment depression on the electrocardiogram (ECG). 
Frequently a combination of these drugs is necessary for 
symptom control.4,5 However, none of these drugs have been 
shown to be disease modifying – their use does not change 
the risk of MI, sudden cardiac death, or all-cause mortality. 
Their mechanism of action is the reduction of myocardial 
oxygen demand (heart rate, afterload, and preload) so that 
the threshold producing anginal symptoms is not reached 
(see Part I of this series1). In practice, this translates to 
lowering rate-pressure product and/or producing systemic 
venodilation, thereby lowering left ventricular end-diastolic 
pressure (LV-EDP) and volume and reducing myocardial wall 
tension. In turn, this permits greater flow in the   epicardial 
coronary arteries and improves myocardial oxygen delivery. 
Relative advantages of each agent with respect to cardiac 
physiology and patient comorbidities permit partial customi-
zation of therapy.
Nitrates
Nitroglycerin, in clinical use since 1878, causes dilation of 
epicardial coronary arteries, even when they are partially 
stenosed, by relaxing arterial smooth muscle. Nitroglycerin 
does not release nitric oxide (NO) directly, as compared with 
sodium nitroprusside. The organic nitrates react with intracel-
lular sulfhydryl groups (eg, from methionine or cysteine) and 
enzymes to produce NO or the intermediate S-nitrosothiol, 
which is reduced to NO. Thus, nitrates are prodrugs that 
undergo enzymatic denitrification within the vascular wall, 
most significantly by mitochondrial aldehyde dehydrogenase. 
NO then activates smooth muscle guanylyl cyclase, raising 
cyclic guanosine monophosphate (cGMP) levels to inhibit 
calcium entry into the muscle cell and relax muscle filaments. 
NO also acts to inhibit potassium channels, hyperpolarizing 
muscle membranes, and activating light chain phosphatase, 
both of which effect relaxation, and may account for a sig-
nificant proportion of vasodilation.6 Similarly, NO activates 
platelet cGMP to reduce intraplatelet calcium concentrations, 
impairing platelet activation to a degree.7 In effect, nitrates 
act as exogenous NO donors, in addition to raising endo- 
genous production of NO.8 Although the predominant effect 
of nitrates is to reduce preload, ie, produce venodilation, with 
greater activity in the venous than arterial beds, at higher 
doses its direct effect upon arteries is more pronounced, with 
a greater reduction in blood pressure (BP) and afterload. The 
net result is a reduction in myocardial oxygen consumption, 
but an overall increase in exercise capacity in patients with 
CAD as well, permitting a greater total workload before 
angina is triggered. In addition, NO improves endothelial 
function, which contributes to vasodilation and optimizes 
vascular reactivity.9,10 Finally, nitroglycerin redistributes 
coronary blood flow from normally perfused areas of myo-
cardium to ischemic zones.11,12 A reduction in ventricular 
diastolic pressure and an increase in collateral blood flow 
play a part in this phenomenon, favoring subendocardial 
perfusion relative to the subepicardial. In an experimental 
model of coronary vasospasm, the observed rise in blood 
flow to the ischemic myocardium produced by nitroglycerin 
was not accompanied by diminished perfusion in normal 
myocardium.13
Sublingual nitroglycerin is readily absorbed through 
mucous membranes, and its effect is prompt (1–3   minutes), Vascular Health and Risk Management 2010:6
Table 1 Common forms of nitrates used as anti-ischemic agents in angina
Compound Route Usual dose (daily unless mentioned) Onset of  
action, min
Duration
Nitroglycerin Sublingual 0.3–0.6 mg up to 1.5 mg as needed, up to 3 tabs 2–5 10–30 min
Spray/mist/aerosol 0.4 mg, 1–2 sprays prn as needed, up to 3 doses 5 min apart 2–5 10–30 min
Ointment 2% 7.5–40 mg, 6 × 6 in or 15 × 15 cm 20–60 3–8 h
Transdermal patch 0.2–0.8 mg/h q24 h; remove at night for 12 h .60 8–12 ha
intravenous 5–200 µg/min (used in ACS) titrated to symptom relief, headache,  
or hypotension
1–2 while 
infusingb
isosorbide dinitrate Oralc 5–80 mg, 2–3 times daily 30–60 4–6 h
isosorbide mononitrate Oral 20 mg twice daily, 7–8 h apart 30–60 6–8 h
isosorbide mononitrate SR Oral 30–240 mg daily, given once daily 30–60 12–18 h
aRequires 8–10 h nitroglycerin free recovery period because of tolerance; bMay exhibit tolerance in 7–8 h; cAlso available in sublingual form.
Abbreviations: q24 h, every 24 hours; ACS, acute coronary syndrome; SR, sustained release.
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reliable, and more effective than other forms, such as sprays, 
ointments, transdermal patches, and sustained release 
preparations. It should be offered to all patients with angina 
unless there are contraindications. Duration is on the order 
of 30 minutes. Patients should use nitroglycerin prophylacti-
cally about 5 minutes prior to any stress or activity that is 
known to produce angina, as well as for acute events. Side 
effects include cerebral vasodilation and headache, postural 
hypotension, dizziness, and rarely, syncope in hypovolemic 
patients. If angina is unrelieved after using up to 3 sublingual 
tablets or sprays, patients should be instructed to go the emer-
gency department promptly for further care. Nitroglycerin is 
adsorbed by plastic containers and deteriorates with exposure 
to light, humidity, and ambient air. Even when stored in small 
brown glass containers seemingly tightly sealed, potency may 
be lost over time, so regular replacement is prudent.
Long-acting nitrates in common use include an ointment, 
patches, isosorbide dinitrate and its metabolite, isosorbide 
mononitrate (Table 1).14 None is as effective as the sublingual 
form, and higher doses of oral forms are necessary because of 
first-pass metabolism by hepatic glutathione reductases. Iso-
sorbide mononitrate is the exception. These agents effectively 
extend the duration of action of sublingual nitroglycerin, 
but since response is less predictable, individual titration is 
advised. Although they are convenient in once-daily doses, 
none provide full 24-hour protection.15 Tolerance develops 
within 12–24 hours, which may be avoided with a nitrate-
free period of about 8 hours each day.16,17 Patients using 
patches must remember to remove them at night. Proposed 
mechanisms for tolerance18 include (1) overproduction of 
superoxide and/or peroxynitrite-free radicals which inactivate 
NO, preventing vasodilation to both endogenous and exog-
enous NO and raising responsiveness to vasoconstrictors;19 
(2) impaired bioactivation of nitroglycerin resulting from 
limited availability of sulfhydryl groups;20 (3) inhibition of 
mitochondrial aldehyde dehydrogenase, which regulates 
biotransformation of nitrates to NO;21,22 (4) expansion of 
plasma volume, with or without (5) additional release or 
enhanced sensitivity to catecholamines, angiotensin II, or 
other vasoconstrictors; (6) upregulation of cGMP-dependent 
kinase type Iβ, an isoform of the predominant type cGKIα, 
much less efficient in activating the large-conductance 
Ca2+-dependent potassium channel (BK channel), which is 
responsible for vascular smooth muscle relaxation.23,24
cGMP-dependent phosphodiesterase inhibitors (type 5 
or PDE5), such as sildenafil (Viagra), tadalafil (Cialis), 
and vardenafil (Levitra), must not be used with nitrates 
within the same 24-hour period because of the risk of severe 
hypotension.5,25 cGMP is degraded by phosphodiesterase, but 
cGMP levels are raised by nitrates. Together with PDE5 inhi-
bition of the degrading enzyme, undue elevations of cGMP 
can lead to hypotension and lower coronary perfusion. Other 
contraindications to nitrate use include obstructive hyper-
trophic cardiomyopathy, severe aortic stenosis, constrictive 
pericarditis, mitral stenosis, or closed-angle glaucoma.
Reflex tachycardia may develop when using nitrates, 
and for this reason, combination with a β-blocker, diltiazem, 
or verapamil is usually advised.5 When used together with 
β-blockers or CCBs, anti-ischemic effects may be syner-
gistic.5 Nitrates and CCBs are effective in Prinzmetal’s or 
vasospastic angina, whereas response to β-blockers is vari-
able or unlikely. Aspirin may worsen ischemic attacks in 
this variant. The forms, doses, onset, and duration of clinical 
nitrates are summarized in Table 1.
β-blockers
Adrenergic receptors are a class of G-protein coupled receptors 
stimulated by the catecholamines, and those in the β-family 
have most effects mediated by adenylyl cyclase.   Specific β1 
effects include increased heart rate and   contractility, increased Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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automaticity and conduction velocity, release of renin from 
juxtaglomerular cells, and lipolysis. β2-adrenergic receptor 
stimulation relaxes smooth muscle in the bronchi and else-
where, dilates peripheral, coronary, and carotid arteries, and 
promotes glycogenolysis and gluconeogenesis, among other 
actions. All β-blockers are effective against anginal pain 
because they lower heart rate, BP, and contractility, thereby 
reducing myocardial oxygen demand. As such, guidelines 
indicate that they should be used as first-line therapy in 
patients without prior MI (class I, level of evidence [LOE]: B) 
and when a previous MI has been sustained (class I, LOE: A) 
unless contraindications exist.5 In addition, because of their 
negative chronotropic effect, β-blockers prolong diastole, 
raising coronary artery blood flow and myocardial perfusion. 
They lower heart rate at rest and limit rises in heart rate dur-
ing exercise, keeping myocardial oxygen demand below the 
threshold at which angina occurs. Most antianginal effects of 
β-blockers result from β1 inhibition. When used alone, there 
is some evidence that β-blockers may be more effective than 
long-acting nitrates or CCBs in reducing ischemic episodes 
when they are mild.26
β-blocker dosages are titrated to a resting heart rate of 
55–60 bpm and an exercise heart rate response ,75% of 
the rate that precipitates ischemia. In patients with severe 
angina, target heart rates of ,50 bpm are sometimes used 
provided no symptoms result and atrioventricular (AV) block 
does not occur. Some β-blockers are partial agonists with 
some intrinsic sympathomimetic activity, which blunts sec-
ondary preventive benefits, and are not used.27 Some newer 
β-blockers, such as labetalol, carvedilol, and bucindolol, 
also have partial α1-adrenergic blocking effects, causing 
  vasodilation. Others have antiarrhythmic class effects – 
  propranolol, metoprolol, and carvedilol a class I effect 
(sodium-channel blockade), and sotalol a class III effect 
(potassium   channel blockade).   Further, carvedilol and its 
metabolites have antioxidant, antiproliferative properties, 
which inhibit apoptosis. Most β-blockers are well absorbed. 
β-Blockers that are lipid-soluble, such as propranolol and 
metoprolol, have shorter half-lives because they are metabo-
lized by the liver. Hydrophilic β-blockers, on the other hand, 
such as atenolol and nadolol, are eliminated renally and 
have longer half-lives. Timolol is among the most potent 
of the β-blockers; labetalol is the weakest. The clinician 
should be familiar with the differences between β-blockers, 
including duration of action, although as far as anti-ischemic 
efficacy is concerned, equipotent doses produce similar 
effects. In larger doses, predominantly β1-blockers may lose 
some specificity and inhibit β2-receptors. Pertinent clinical 
information is   summarized in Table 2.
Adverse reactions of β-blockers
Absolute contraindications to β-blockers are severe or 
advanced bradycardia, conduction system disease (sinus 
node dysfunction and/or high-grade AV block), asthma, 
peripheral vascular disease (PAD) with rest ischemia, depres-
sion, and overt heart failure (HF). Less marked or controlled 
versions of the same phenomena are relative contraindica-
tions. These include a PR interval .0.24 seconds, systolic 
BP , 100 mm Hg, Raynaud’s phenomenon, and pregnancy. 
Rises in triglycerides (TGs) and lower levels of high-density 
lipoprotein (HDL) cholesterol have been reported with 
β-blockers. Fatigue, mild depression, and lack of motivation 
are usually dismissed, but upon careful questioning, these are 
more common barriers to patient adherence than appreciated. 
Similarly, the cause of impotence is difficult to identify in 
men with angina, but an association with β-blockers is well 
described. β-blockers may blunt the tachycardic response to 
hypoglycemia in diabetics, and worsening of hypoglycemia in 
Table 2 β-Adrenergic blockers used to treat angina
Druga Selectivity Dose time to peak action  
after oral intake, h
Elimination  
half-life, h
Dose
Atenolol β1 2–4 6–9 50–200 mg/d
Bisoprolol β1 2–4 9–12 10 mg/d
esmolol, iV β1 2–5 min 9 min 50–300 µg/kg/min
Metoprolold,e β1 1–2 3–6 50–200 mg twice daily
Propranolold None 1–2 3–5 80–120 mg twice daily
Nadolol None 3–4 14–24 40–80 mg/d
Timolol None 1–2 4–5 10 mg twice daily
Carvedilolc,d None 1.0–1.5 7–10 3.125–25 mg twice daily
Labetalolb None 2–4 3–6 200–600 mg twice daily
aDrugs  with  partial  agonist  activity  are  not  included;  bCombined  α-blocking  and  β-blocking  activities;  cCombined  α-blocking,  β1-blocking,  and  β2-blocking  activities; 
dAntiarrhythmic class i effect; eAn extended release formulation may be begun at 100 mg daily.
Abbreviation: iV, intravenous.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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  diabetics on oral agents or insulin has been reported. As a rule 
of thumb, cardioselective agents are preferred in asthmatics, 
diabetics, and patients with PAD, simply because there is less 
interference with bronchodilation, peripheral arterial dilation, 
and glycogenolysis. As mentioned, Prinzmetal’s angina may 
worsen with β-blockers due to an unopposed α-adrenergic 
effect. Patients with cocaine-induced coronary vasoconstric-
tion may also react adversely when given β-blockers, with 
hypertension and seizures. Similarly, since β-adrenergic 
receptors may be up-regulated when patients are treated with 
β-blockers, these agents should not be abruptly discontinued, 
lest rebound vasoconstriction precipitate unstable angina or 
even MI.28,29 Patients with asthma, claudication, or HF whose 
symptoms increase with β-blockers should be reevaluated for 
possible substitution with CCBs and appropriately monitored. 
Sleep disturbances with nightmares and cold extremities may 
also be limiting. On occasion, athletes, exercise enthusiasts, 
and those in cardiac rehabilitation programs may object to 
limitations in heart rate and exercise capacity while using 
β-blockers. In these instances, a solution involving adjust-
ments in exercise details, goals, and β-blocker dose or type 
can usually be negotiated.
Calcium Channel Blockers
CCBs bind to and inhibit L-type calcium channels, reducing 
calcium influx into cells. Intracellular calcium deprivation 
relaxes smooth muscle cells, causing vasodilation in the 
peripheral and coronary beds and increased coronary blood 
flow. The less selective, nondihydropyridine (DHP) CCBs, 
verapamil and diltiazem, also slow sinoatrial (SA) and AV 
nodal conductions to lower heart rate and depress contractility 
under physiological conditions. All the CCBs are effective 
coronary vasodilators. The 2 major subdivisions of CCBs 
are listed in Table 3.
DHPs lower BP and myocardial wall tension to reduce 
myocardial oxygen consumption. A rise in coronary blood 
flow further contributes to correct myocardial oxygen imbal-
ance. These drugs lower the frequency of angina, reduce 
the need for nitrates, extend treadmill walking time, and 
improve ischemic ST-segment changes on exercise testing 
and electrocardiographic monitoring.5,30–32 Amlodipine, in 
particular, may have some independent action in relieving 
diastolic dysfunction other than a reduction in BP.33
CCBs find clinical use in patients who cannot tolerate 
β-blockers, when they are ineffective, and in combination 
for additive anti-ischemic effects. The CCBs in common 
use for angina are summarized in Table 4. Although they 
are effective antianginal agents, they do not modify the 
natural progression of the disease. The large International 
Verapamil-Trandolapril Study (INVEST) trial reported a 
reduction in number of patients with angina from about 
65%–25% using verapamil as compared with atenolol, with 
no difference in mortality over a 2-year period.34 When DHPs 
are used in combination with β-blockers, reflex tachycardia 
from the CCB is blunted. Long-acting DHPs are preferred. If 
clinically needed, verapamil or diltiazem may be used with 
caution to lower heart rate or slow AV conduction further 
when ventricular function is preserved. In patients with 
stable angina and hypertension, β-blockers in combination 
with amlodipine and long-acting nifedipine, nicardipine, 
isradipine, or felodipine offer an advantage. Of all agents 
available, the greatest clinical experience has been with 
amlodipine and felodipine.
Short-acting nifedipine has been linked to an increase 
in MI and should be avoided in unstable angina or acute 
coronary syndromes (ACS). The A Coronary Disease Trial 
Investigating Outcome with Nifedipine GITS (ACTION) 
study showed that long-acting nifedipine (gastrointestinal 
therapeutic system) safely relieved angina and prolonged 
event-free survival in patients with stable angina and 
hypertension.35,36 Verapamil acts chiefly through a negative 
inotropic action, with less associated reflex tachycardia; 
Table 3 CCBs are classified chemically, which reflects their properties
Type Properties Examples
Dihydropyridines (DHP) Peripheral and coronary vasodilators, negative inotropic action Amlodipine, nifedipine, felodipine,   
isradipine, nicardipine, nisoldipine
Nonhydropyridines (non-DHP)
Phenylalkylamine Additional negative chronotropic and inotropic actions Verapamil
Benzothiazepine Additional negative chronotropic and inotropic actions Diltiazem
Mixed sodium and CCB Nonselective, blocking delayed rectifier K+ current and fast Na+ current.  
Also inhomogeneous electrical effects, prolonged QT interval,  
and linked to torsade de pointes. Not in current use
Bepridil
Antihistamine Used for migraine prophylaxis, PAD, vertigo, but not for angina. Flunarizine
Abbreviations: CCBs, calcium channel blockers; PAD, peripheral vascular disease.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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diltiazem has greater vasodilatory actions than verapamil. 
Both verapamil and diltiazem are contraindicated in patients 
with uncompensated HF because of their negative inotropic 
effects; amlodipine and felodipine appear safe when LV 
dysfunction is compensated.35 Use of non-DPHs after com-
plex MIs should be avoided because of the possibility of 
HF as well.37,38 DHPs, particularly nifedipine, are effective 
in managing Prinzmetal’s variant angina along with long-
acting nitrates.
Although CCBs are effective anti-ischemic agents, in 
patients with unstable angina/ST segment elevation myo-
cardial infarction (STEMI), they do not improve mortality. 
Diltiazem and verapamil are contraindicated in patients with 
STEMI accompanied by systolic LV dysfunction and HF. 
Immediate release forms of DHP CCBs are contraindicated 
in STEMI because reflex tachycardia increases myocardial 
oxygen demand and hypotension potentially lowers coronary 
perfusion pressure. Also, they should not be used in unstable 
angina/STEMI without a β-blocker.
Common side effects of headache, dizziness, flushing, and 
edema are due to vasodilation. Interaction with other nega-
tive chronotropic or inotropic agents to produce bradycardia, 
heart block, or HF has been reported. CCBs may also suppress 
lower esophageal sphincter contraction and worsen symptoms 
of gastroesophageal reflux disease. CCBs inhibit the CYPA4 
enzyme in the liver and, therefore, may raise levels of statins 
and many other drugs, which may be overlooked.39 Cimetidine 
and grapefruit juice may raise the effective level of CCBs. Since 
magnesium is a calcium antagonist, magnesium supplements 
may enhance the actions of CCBs, particularly nifedipine.
Summary
A comparison of the relative physiological effects of the 
3 traditional anti-ischemic agents is summarized in Table 5.
Although efficacious, traditional anti-ischemic agents 
do not produce relief in all patients, and individual variation 
in responsiveness is well known. In a meta-analysis of all 
3 types of agents, nitrates, β-blockers, and CCBs, β-blockers 
lowered the frequency of anginal attacks better than CCBs, 
not including amlodipine and felodipine.30 The combination 
of β-blockers with nitrates is favored because they both 
lower myocardial oxygen demand and raise subendocardial 
blood flow through different mechanisms, whereas the 
β-blockers prevent potential reflex tachycardia from nitrate-
induced hypotension, and nitrates modify any potential rise 
in LV-EDP or preload from negative inotropic actions of 
the β-blockers (Table 5). β-blockers combined with DHP 
CCBs improve exercise duration more than either alone and 
Table 4 CCBs used for ischemic heart disease
Drug Duration of action Usual dose Common side effects
Dihydropyridines (DHP)
Nifedipine, slow release Long 30–180 mg/d Hypotension, edema,  
dizziness, flushing,  
nausea, constipation
Amlodipine Longa 5–20 mg qd Headache, edema
Felodipine, SR Long 5–10 mg qd Headache, edema
isradipine, SR Medium 2.5–10 mg bid Headache, fatigue
Nicardipine Short 20–40 mg tid Headache, edema,  
dizziness, flushing
Nonhydropyridines (non-DHP)
Diltiazem, immediate release Short 30–80 mg qid Hypotension, dizziness,  
flushing, bradycardia,  
edema
Diltiazem, slow release Long 120–320 qd Hypotension, dizziness,  
flushing, bradycardia,  
edema
Verapamil, immediate release Short 80–160 mg tid Hypotension, negative  
inotropism, HF,  
bradycardia, edema
Verapamil, slow release Long 120–480 mg qd Hypotension, negative  
inotropism, heart  
failure, bradycardia,  
edema
aHas the longest half life of the CCBs of 35–50 h.
Abbreviations: CCBs, calcium channel blockers; SR, sustained release; tid, 3 times a day; qid, 4 times a day; qd, daily; HF, heart failure.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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trial   comparing it to isosorbide mononitrate, nicorandil was 
found to be both safe and efficacious in treating angina.50 A 
dose of 10–40 mg twice daily controls 70%–80% of stable 
chronic angina patients, with an effect maintained for about 
12 hours.51 This drug is not yet approved for use in the United 
States, but it is available in other countries.
Ivabradine is a prototype of specific bradycardic agents 
and the only one in use and under current clinical investiga-
tion. These compounds selectively inhibit the inward sodium–
potassium “If current,” an important pacemaking current in 
SA node cells, to slow the rate of diastolic depolarization and 
lower heart rate.52 Ivabradine does not affect contractility, AV 
nodal conduction, nor alter hemodynamics.
Phase II studies confirmed the bradycardic effect of 
ivabradine at rest and during exercise, as well as antianginal 
efficacy.53,54 In noninferiority trials, ivabradine compared 
well to atenolol55 or amlodipine.56 The BEAUTIFUL trial57 
found that in patients with CAD, LV dysfunction, and heart 
rates .70 bpm, ivabradine was able to lower the risk of acute 
myocardial infarction (AMI) and need for revascularization 
by one-third, even when therapy was considered optimal. In 
the overall study, population without higher heart rates, the 
reduction in heart rate induced by the agent (average, 6 bpm) 
did not result in a significant reduction of the primary com-
posite end point (cardiovascular death, hospital admission for 
AMI, and admission for HF). The ASSOCIATE trial58 found 
that ivabradine titrated to a dose of 7.5 mg twice daily after 
4 months, increased total exercise duration in concert with 
reductions in rate-pressure product at rest and at the peak of 
exercise, in patients taking atenolol 50 mg daily. Ivabradine is 
another well-tolerated agent in practitioners’ toolkits that may 
be added to nitrates and β-blockers for additional antianginal 
effect or used in patients who cannot take β-blockers. It is not 
yet approved in the United States. About 15% of patients expe-
rience a curious brightness in the visual fields because the drug 
also blocks a retinal current with similar characteristics. This 
side effect is transient and reversible, but in 1% of patients, 
ivabradine has to be discontinued. Other adverse reactions, 
including conduction abnormalities, occur in #10% of the 
cases. Ivabradine should not be used with CYP3A4 inhibitors 
or in patients with sinus node dysfunction.
Trimetazidine, a member of the class of “3-ketoacyl 
coenzyme A thiolase (3-KAT) inhibitors,” is a metabolic 
modulator that improves myocardial energetics at several 
levels,59 partially inhibiting β-oxidation of fats by decreas-
ing activity of mitochondrial enzyme 3-KAT.60,61 The drug 
raises myocardial glucose utilization, prevents a decrease 
tolerance is acceptable,40 but the combination of β-blockers 
with verapamil is still generally to be avoided. On the other 
hand, amlodipine along with β-blockers is more effective 
than either one alone41 since coronary blood flow increases 
with a fall in BP from amlodipine, but the CCB lowers heart 
rate and contractility, providing 4 near-orthogonal ways to 
improve myocardial oxygen balance. Hard data on the use of 
all 3 classes of agents together are lacking. In 1 analysis, use 
of all 3 traditional agents still resulted in an average residual 
of 2 attacks of angina per week among participants.42 About 
5%–15% of patients are refractory to “triple therapy”.43
Newer, nontraditional anti-ischemic agents
Nicorandil is structurally a nicotinamide derivative with 
a nitrate moiety and a dual mechanism of action. First, it 
increases potassium ion conductance by opening adenosine 
triphosphate (ATP)-sensitive potassium channels, in turn 
activating the enzyme guanylate cyclase. Second, nicorandil 
shares the smooth muscle-relaxing property of nitrates to 
vasodilate, lowering preload through venodilation. The 
drug also reduces afterload and promotes expression of 
endothelial NO synthase.44 Use is associated with improved 
myocardial function during ischemia-reperfusion,45,46 protec-
tion of myocardium during ischemia,44,47 shortened action 
potential duration, and prevention of intracellular calcium 
toxicity, of importance in modulating ischemic cell damage 
and death. In the Impact Of Nicorandil in Angina (IONA) 
study of 5,126 patients with angina,48 nicorandil produced a 
significant 17% reduction in hospitalization for chest pain, 
MI, and CAD death. The drug also prolongs time to the 
onset of angina and ischemic ECG changes, extends exer-
cise duration,49 and reverses ischemia-related impairment in 
regional wall motion. In the multicenter, randomized SNAPE 
Table 5 Cardiovascular effects of nitrates, CCBs, and β-blockers 
in angina
Variable Nitrates Calcium 
channel  
blockers
β-blockers
Collateral blood flow ↑↑ ↑↑ →
endomyocardial to  
epimyocardial flow
↑↑ ↑ ↑
Heart rate ↑ (reflex) ↑↓ (reflex) ↓↓
Left ventricular wall  
tension
↓↓ ↓ ↑→
Myocardial  
contractility
↑ (reflex) ↑ ↓→ (reflex) ↓↓
Cardiac work ↓↓ ↓↓ ↓↓
Abbreviation: CCBs, calcium channel blockers.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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in ATP and phosphocreatine levels in response to hypoxia 
or ischemia, preserves ionic pump function, minimizes 
free radical production, and protects against intracellular 
calcium overload and acidosis. It raises coronary flow 
reserve, lowers frequency of anginal episodes, improves 
exercise performance, and spares the use of nitrates62 with-
out changes in heart rate, negative inotropic, or vasodilator 
actions. Trimetazidine may be added to ongoing therapy 
with β-blockers, CCBs, and nitrates with safety. The TIGER 
study63 confirmed the usefulness of this agent in elderly 
patients resistant to traditional anti-ischemic agents with 
effects mediated through hemodynamic changes. A Cochrane 
review64 of 1,378 patients found that the drug was extremely 
well tolerated and agreed with the above-mentioned findings. 
Multiple intracellular metabolic and electrophysiological 
benefits have created an interest for possible use in HF and 
idiopathic dilated cardiomyopathy.65–67
Rho kinase, or “ROCK”, is an important intracellular 
enzyme which phosphorylates proteins to affect a number of 
cellular functions, among them phosphorylation of myosin, 
resulting in smooth muscle contraction and vasoconstriction. 
Fasudil is a rho-kinase inhibitor that has been used to prevent 
vasospasm, especially in the pulmonary and cerebral arterial 
beds, in addition to inhibiting production of vascular endothe-
lial growth factor. A phase II, multicenter, double-blind 
trial found that the agent prolonged the time to ST-segment 
depression on exercise testing, improved exercise duration, 
and significantly reduced the number of anginal attacks.68 The 
drug is effective and safe in patients with stable angina who 
are already being treated with traditional agents.
Ranolazine, which first attracted clinical attention in the 
1980s, is the newest antianginal agent to receive approval 
from the US Food and Drug Administration in nearly 
30 years, presently for use in patients uncontrolled by tra-
ditional agents. It is an important, welcome, and needed 
addition to the armamentarium of clinical cardiologists who 
manage patients with angina.
Normally, mitochondrial production of ATP provides the 
energy for the function of both sarcolemmal Na+/K+-ATPase 
and sarcoplasmic reticulum Ca2+-ATPase (transfers calcium 
from the cytosol to the sarcoplasmic reticulum lumen). The 
potential energy stored in the electrochemical Na+ gradi-
ent established by the former usually furnishes the power 
for calcium removal from the intracellular to extracellular 
space by the Na+/Ca2+ exchanger (NCX). Ischemia impairs 
ATP synthesis, and since maintenance of ionic gradients is 
energy-intensive, ATPase function falls, limiting removal 
of intracellular sodium. Hence ischemia eventually causes 
intracellular sodium overload, followed by intracellular 
calcium accumulation via reverse-mode NCX1-activity, 
further mitochondrial inhibition, and extracellular potassium 
accumulation.69
Sodium enters the myocyte rapidly during the initial 
depolarization or upstroke of the cardiac action potential, 
but it may be followed by a late inward sodium current that 
persists significantly throughout the ensuing action potential 
when the myocyte is diseased. This late sodium current 
was initially ascribed to failure of fast sodium channels to 
close, but evidence indicates there are separate late sodium 
channel(s). Normally, late sodium inward current is small, 
about 1% of the total inward sodium flux. Ischemia (and HF) 
increases the late inward sodium current, which becomes 
a much larger proportion of the total sodium entering the 
cell.70–73
Intracellular sodium (Na+) overload, through the reverse 
NCX mechanism mentioned above, leads to excess level of 
intracellular calcium and continued exposure of actin and 
myosin to calcium, causing a tonic contracture in isolated 
fibers, but diastolic stiffness in the intact heart. This extra 
contractile work wastes energy and compresses the vascular 
space during diastole, reducing myocardial oxygen supply 
even more.70,74–76 The rise in intracellular sodium concentra-
tion causes electrical instability, promoting arrhythmias. 
Intracellular sodium overload and the subsequent rise in 
intracellular calcium play a large role in myocardial stunning 
and reperfusion injury.77–80 Stunned myocardium has suffered 
transient ischemia with LV dysfunction, but perfusion is 
preserved at rest, and myocytes remain viable. There may 
be a 50% reduction in ATP content in stunned myocardium, 
which can require days to fully replete, as recovery occurs 
in postischemic contractile dysfunction. Although ischemic 
episodes may be multiple or prolonged, the severity of meta-
bolic impairment remains insufficient to result in irreversible 
cell injury, muscle loss, or disrupt cell membrane integrity.81,82 
Subsequent reperfusion, however, may cause myofibrillar 
damage. Even though reversible, stunned myocardium may 
be less responsive to inotropic drugs and may lead to severe 
hemodynamic changes, even cardiogenic shock.
Ranolazine is a piperazine derivative that inhibits the late 
sodium channels, not only lowering total inward sodium flux 
but also the subsequent intracellular calcium overload.83–86 
At therapeutic concentrations, fast inward sodium current 
is unchanged, and reduction of late inward sodium current 
is confined to ischemic or failing myocytes. By blunting the 
amount of excess sodium entering the cell, the total intracel-
lular sodium concentration is restricted, thereby limiting the Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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ischemia-associated calcium overload, the lethal component 
of events.75,76,87 The drug interrupts the positive feedback loop 
that perpetuates myocardial ischemia, sodium influx, loss of 
potassium, voltage gradient perturbations, and myocardial 
dysfunction. By preventing intracellular sodium overload, 
calcium accumulation is thwarted, diastolic muscle relax-
ation is normalized,88 and myocardial oxygen balance and 
myocardial blood perfusion are preserved. Improvement in 
the dual changes in intracellular sodium and calcium pro-
motes electrical stability, minimizing the proarrhythmogenic 
effects of ischemia. Ranolazine also reduces the late inward 
calcium current, the inward Na+/Ca2+ exchange current, and 
the outward repolarizing, delayed rectifier potassium current. 
Ion channel changes induced by ranolazine resemble those 
of amiodarone.74
Peak plasma levels occur 4–6 hours after an oral dose, 
with 50%–55% bioavailability. Ranolazine is cleared by 
the hepatic enzymes CYP3A4 (70%–85%) and CYP2D6 
(10%–15%) and is also a substrate of P-glycoprotein, a widely 
expressed membrane transporter protein.89 P-glycoprotein 
inhibitors, such as cyclosporine, reduce the dose of ranola-
zine needed to produce a given response. As a result of these 
pharmacokinetic properties, there are a number of clinical 
drug interactions of importance:
•	 Ketoconazole significantly raises ranolazine levels up to 
4.5-fold, as would other CYP3A4 inhibitors, potentially 
increasing such side effects as dizziness, headache, 
and nausea. This applies to clarithromycin, ritonavir, 
nefazodone, rifampin, rifabutin, rifapentin, barbiturates, 
carbamazepine, phenytoin, St John’s wort, grapefruit 
juice, and many other CYP3A4 interactants.
•	 Diltiazem, due to mild CYP3A4 inhibition, may raise 
ranolazine levels 1.5-fold.
•	 Paroxetine may raise plasma ranolazine concentrations 
by a factor of 1.2 because of CYP2D6 inhibition.
•	 Ranolazine may nearly double levels of simvasta-
tin since it is a mild inhibitor of both CYP3A4 and 
CYP2D6. Simultaneous administration of CYP3A4 
inhibitors together with some statins remains a clinical 
concern.39,90
•	 Since verapamil inhibits P-glycoprotein in doses 
of $360 mg/d, this CCB may raise ranolazine levels up 
to 3-fold.
•	 Digoxin levels may rise 1.4–1.6-fold because of 
  P-glycoprotein competition by ranolazine.
•	 Ranolazine may prolong the rate-corrected QT interval, 
about 6 msec at a dose of 2 g/d. This would affect patients 
with congenital long QT syndrome or who take drugs that 
prolong the QTc interval including class Ia (eg,   quinidine) 
or class III (eg, dofetilide, sotalol, amiodarone) antiar-
rhythmic agents, erythromycin, amitriptyline, some 
antipsychotic agents (eg, thioridazine, ziprasidone), and 
others.
The clinical trials mentioned below eliminated partici-
pants who were taking such drugs, so data concerning the 
significance and extent of these interactions are lacking. 
Drug-induced prolongation of QT intervals is an important 
determinant of potentially lethal arrhythmias in both outpa-
tient and inpatient settings.91–93
Early ranolazine trials confirmed a significant prolon-
gation in exercise duration to angina and to ST-segment 
depression (1 mm) in angina patients.94,95 In the first of the 
4 major clinical studies, the MARISA trial96 used a crossover 
design, which probed the effects of 3 doses of ranolazine in 
191 stable angina patients previously responsive to nitrates, 
β-blockers, and/or CCBs. Total exercise duration and time 
to onset of angina and to 1-mm ST-segment depression 
were all increased. A maximal dose of 1,000 mg twice daily 
was established as effective and safe. The CARISA trial97 
confirmed similar effectiveness of ranolazine in 823 patients 
who continued to have effort angina despite use of atenolol, 
diltiazem, or amlodipine. In the Ranolazine Open Label 
Experience (ROLE) extension program,98 about 900 patients 
who participated in the MARISA or CARISA trials enrolled 
in an additional study to evaluate any ranolazine effect upon 
survival. Data did not reflect any deviation from the historical 
annual mortality of 4%–13% from counterparts not receiv-
ing the drug.99,100 After approximately 2 years of monitoring, 
23% of patients discontinued ranolazine because of dizziness 
(12%) or constipation (11%). The Efficacy of Ranolazine In 
Chronic Angina (ERICA) trial101 showed ranolazine was use-
ful when combined with nitrates and amlodipine in patients 
who had already been taking maximal doses of conventional 
anti-ischemic agents.
In the Metabolic Efficiency with Ranolazine for Less 
Ischemia in Non–ST-Segment Elevation Acute Coronary 
Syndromes 36 (MERLIN-TIMI 36) trial,102,103 6,560 patients 
with CAD who were enrolled in the MERLIN study of 
non-ST-segment elevation ACS were randomized to either 
ranolazine in an intravenous bolus followed by oral therapy 
or placebo. Ranolazine did not affect the composite of cardio-
vascular death, MI, or recurrent ischemia.102 However, further 
analysis revealed a reduction in angina and improvement 
in exercise duration with an acceptable safety profile. The 
study also suggested an antiarrhythmic effect, and a small 
reduction in HbA1c was observed in diabetics. Confirming Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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the efficiency of ranolazine to relieve ventricular wall stress 
by lowering myocardial sodium and calcium overload, these 
same investigators recently reported efficacy in a high-risk 
subgroup of STEMI patients with elevated concentrations 
of B-type natriuretic peptide (BNP).104 Such patients with 
high levels of BNP and the N-terminal portion of BNP pro-
hormone, resulting from, and proportional to, the volume 
of myocardium that is ischemic, stiff, and dysfunctional, 
are at high risk for adverse cardiovascular events. Although 
preliminary, these data extend our information and unite a 
potent new agent with a specific application of this biomarker 
to improve patient outcomes.105
Options for refractory angina
Refractory angina refers to patients who have continued 
angina, usually Canadian Cardiovascular Society (CCS) 
class III/IV, and objective evidence of ischemia despite 
optimum medical therapy, but who are not candidates for 
revascularization. In the United States, as many as 1.7   million 
patients are believed to have refractory angina, usually in 
the setting of advanced heart disease. Patients have a bleak 
future, with an annual rate of non-fatal MI of 3.2% and annual 
mortality of 1.8%. Treatment options for refractory angina are 
limited and include spinal cord stimulation (SCS) (invasive 
and multimechanistic), enhanced external counterpulsation 
(EECP) to raise myocardial perfusion, and angiogenesis 
through extracorporeal cardiac shock wave therapy (nonin-
vasive), transmyocardial laser revascularization (invasive), 
or stem cell/gene therapy (invasive and preclinical). After 
intensive reevaluation, some patients with refractory angina 
have eventually been treated successfully with percutaneous 
coronary intervention (PCI).106
EECP consists of the application of 3 pairs of pneumatic 
cuffs placed on the lower extremities at the levels of the 
calves and lower and upper thighs. Cuff inflation and defla-
tion are synchronized with the ECG. At the onset of diastole, 
the cuffs are sequentially inflated from the calves proximally 
to the lower and upper thighs. Before the onset of systole, all 
cuffs are simultaneously deflated. The pressure created dur-
ing inflation increases venous return and diastolic blood flow 
in the coronary arteries and other vascular beds in a manner 
similar to intra-aortic balloon counterpulsation.107,108 The 
simultaneous presystolic decompression in the cuffs reduces 
afterload so that the ejection fraction (EF) improves,109 
whereas the work of the heart diminishes.110 Nonrandomized 
smaller studies reported improvements in perfusion imag-
ing, angina classification, increased exercise tolerance, and 
longer time to ST-segment depression during stress testing 
after EECP use in patients. Improved endothelial function111 
and reduced levels of inflammatory cytokines have also been 
identified.112 It is believed that vasoactive moieties, including 
NO, vascular endothelial growth factor, and endothelin play a 
part in producing these effects.113 The MUlticenter STudy of 
Enhanced External CounterPulsation (MUST-EECP) trial114 
was a multicenter, randomized study that found a 15% rise in 
the time to the onset of 1-mm ST-depression, together with 
25% fewer anginal episodes per week after EECP therapy. 
The International EECP Registry115 reported a reduction 
in angina episodes, lowering of angina class, reduction in 
use of nitrates, with 41% of registrants remaining angina-
free during a 2-year period following treatment. EECP 
may also lower peripheral vascular resistance or mimic a 
training effect that has been likened to the effect of physi-
cal exercise.116 Approximately 62% of patients treated with 
EECP maintain benefits for 1 year, whereas 29% of patients 
sustain improvement for 24 months,117 some even as much 
as 5 years.118 Whether endurance of EECP effect is related 
to an increase in   number and colony-forming capacity of 
circulating endothelial progenitor cells is unknown.119
A typical course of EECP includes 35 1–2 hour sessions 
over 7 weeks. The American College of Cardiology/American 
Heart Association (ACC/AHA) guideline assignment is Class 
IIb, LOE: B5 (see Table 7 caption for key).
In conclusion, EECP provides a noninvasive, effective 
alternative for treatment of refractory angina, capable of 
improving ventricular function, systolic BP, coronary perfu-
sion, myocardial oxygen balance, and exercise tolerance. The 
treatment lowers the number of anginal episodes and spares 
nitrate use in an impressive proportion of patients, which 
may endure for years.120–124
SCS involves implantation of an epidural electrode 
between levels C7 and T1 by puncturing the epidural space 
at T6-7. Generally, the stimulation electrode is connected to 
an external portable stimulator for a trial period. After angina 
frequency and intensity have been significantly reduced, the 
stimulation wire is connected to an implanted stimulator in 
the left abdomen. A magnetic hand-held control device turns 
the unit on and off and adjusts stimulation intensity within 
programmed parameters.
Originally, it was thought that stimulating large afferent 
fibers in the dorsal columns simply blocked impulses from 
the nociceptive afferent nerves carrying cardiac pain signals, 
according to the gate control hypothesis.125–131 SCS raises 
release of the inhibitory neurotransmitter γ-aminobutyric 
acid, lowering the amount of 2 excitatory amino acids, glu-
tamate and aspartate, which in turn suppresses processing Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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of the nociceptive Aδ and C nerve fibers. In addition, SCS 
also raises β-endorphin release, lowering pain perception.132 
Recent data, however, show that additional mechanisms also 
account for the effects of SCS, including sympatholytic 
activity under stress conditions133 and changes in cerebral 
blood flow.134 Although there is little question that SCS 
improves time to ST-segment depression, total exercise time, 
anginal class, quality of life (QoL), and reduces the number 
of hospitalizations and outpatient visits,135–140 a purported 
increase in myocardial perfusion remains unsettled. SCS 
lowers catecholamine levels, and inhibition of tonic sympa-
thetic tone may dilate coronary microvasculature, increasing 
myocardial perfusion, lowering the rate-pressure product 
and hence myocardial oxygen consumption.141,142 Recently, 
a 52% (range, 33%–65%) reduction in sympathetic activity 
was documented during SCS activity during heart rate vari-
ability recordings.143
Randomized clinical trials using SCS have reported a 39% 
increase in time to onset of ST depression and 19% prolonga-
tion in treadmill time, together with a 41% fall in number of 
anginal episodes and 48% decrease in nitrate use.144 In the 
ESBY study,145 104 patients with severe angina and increased 
surgical risk – expected to benefit with only symptomatic 
relief from surgery – were randomized to either SCS or 
coronary artery bypass surgery (CABG). SCS was as effec-
tive as SCS in lowering number of anginal attacks but with 
far less mortality and stroke. After 5 years, both survival and 
QoL were about equal in both groups.146
Complications from SCS include lead migration (13.2%), 
lead breakage (9.1%), and infection, either at the epidural 
site or at the abdominal pouch (3.4%).139 Fortunately, the 
chest pain of AMI is not concealed by SCS. There is no 
interference with pacemakers as long as strict bipolar right 
ventricular sensing is used. Use in patients with ICDs is 
possible, although only case studies are available.147 The 
typical SCS treatment consists of three 1-hour stimulations 
daily. The ACC/AHA guideline grade assigned is class IIb, 
LOE: B.5 In conclusion, SCS is a safe and effective proce-
dure for refractory angina, considered a possible substitute 
for revascularization and is comparable to percutaneous 
myocardial laser revascularization, another option to treat 
refractory angina.148,149
Low-energy, electrohydraulic shock wave therapy is 
an additional option to induce neovascularization.150–152 
A longitudinal acoustic wave is applied to the heart to 
  create a so-called “cavitation effect” producing membrane 
drag and shear stresses. Hyperpolarization, ras activation, 
  nonenzymatic upregulation of NO synthesis, and vascular 
endothelial growth factor and its tyrosine kinase receptor 
flt-1 are believed to be mediators of an eventual anti-ischemic 
effect. The technique has been used in the treatment of hind 
limb ischemia, resistant stress fracture, chronic plantar fas-
ciitis, and wound healing after vein harvesting in coronary 
bypass surgery to induce angiogenesis.
Other treatments for refractory angina not discussed 
are intermittent urokinase therapy43,153,154 and heart trans-
plantation.
Risk factor reduction and prevention
After relief of pain, involving a reduction in the frequency, 
number, and intensity of anginal attacks and restoration 
of the patient’s QoL, the second major goal in therapy of 
angina is risk factor reduction, to slow the progression of 
atherosclerosis, and hopefully forestall deadlier ischemic 
syndromes, such as AMI and sudden cardiac death. The 
importance of a systematic, comprehensive, and monitored 
program using available guidelines as a reference base cannot 
be overemphasized.
Risk factors and prevention – epidemiological notes
The Framingham Heart Study (FHS)155 began in 1948, with 
the announced intention of identifying the common fac-
tors that contributed to the development of cardiovascular 
disease. The legendary contributions of the founding inves-
tigators fundamentally changed the practice of cardiology 
and shaped future-related research activities. Their work 
established the basis for the common source epidemic of 
CAD humans now face. The term “risk factor” was first used 
by Dr Thomas Royle “Roy” Dawber, Director of the FHS 
from 1949–1960, in a landmark 1961 paper156 identifying 
hypertension, hypercholesterolemia, and arrhythmias as risk 
factors, but also referring to smoking. A seminal paper that 
followed157 used risk factors for prediction, beginning a new 
era in preventive cardiology.
Although Hippocrates regarded epidemics as diseases 
“visited upon” a population, as opposed to endemics that 
“reside within” a population, our present epidemic of CAD 
is actually imposed upon us by our own doing. Clearly this is 
an epidemic, occurring rapidly in numbers exceeding normal 
expectancy and arising from common sources, namely, inor-
dinate rises in similar risk factors that are widely prevalent.
A risk factor is a quantifiable, “independent” variable, 
statistically associated with a specific disease, which predicts 
patient risk and hence relates to prevalence in a population. 
Once risk factors are identified, their predictive ability is 
assessed and defined. Implications for different approaches to Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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prevention and optimal treatment are then typically explored. 
Risk factors tend to occur together or cluster, and when they 
do their effects are not simply additive, but generally amplify 
each other. As a result, patients with 2 or more risk factors 
may increase their risk of CAD 4-fold, and those with 3 risk 
factors may face a risk 8-fold to 20-fold greater than those 
with no risk factors.158 Moreover, traditional major risk fac-
tors for CAD are not truly independent in the mathematical 
sense. If a risk factor retains its statistical association with an 
outcome after other risk factors are included in a model, it 
is considered independent. Independence depends upon the 
other variables included in the model, and inclusion of one 
may negate the independence of another. Independent risk fac-
tors may not be causes; causal factors may not be independent 
risk factors, and biomarkers used to judge efficacy of different 
treatments may not be risk factors.159 Thus, risk factors for 
CAD may have an astonishingly complex relationship with 
one another and with the many biochemicals, receptors, and 
markers involved in the pathophysiology of the disease.
The goal of medicine is to prevent disease, relieve suf-
fering, and prolong life.160 Prevention has several meanings. 
Usually when primary care physicians refer to prevention, 
they mean vaccinations, screening tests to detect early 
  pathology, and agents they prescribe to lower risk. Their 
contribution is clinical, individual, and disease-based. Often 
causal risk factors become surrogates for disease and are 
treated as diseases themselves. To epidemiologists, preven-
tion means postponing or limiting the development of dis-
ease. Cardiologists speak of primary prevention to prevent or 
postpone CAD in people without the diagnosis and secondary 
prevention to avert recurrence of cardiac events in patients 
already diagnosed with heart disease. The interventional 
approach in high-risk individuals may produce abbreviated 
results because subsequent adherence to lifestyle counseling 
and prescription drugs is poor, and without risk factor reduc-
tion, the disease progresses after PCI or CABG. When risk 
factors, such as LDL or hyperglycemia, are treated rather 
than the person or the disease, neither the cause nor the total 
outcome is addressed. The cause of the “risk factor” elevation 
may lie in overconsumption of calories and lack of exercise, 
and the outcome may be influenced by much more than the 
“risk factor” because it is only a surrogate for the outcome.
Prevention may also mean what the patient can do per-
sonally to avoid disease, owned lifestyle changes that may 
be extremely effective when continued over a prolonged 
period of time. Such prevention through lifestyle does not 
allow risk factors to develop in the first place and is more 
fundamental and complete than primary prevention. Since the 
incubation period of CAD is long, extending over decades, 
and begins much earlier than believed, all personal   preventive 
measures are best begun as early as medically appropriate and 
be consistently applied over years. Furthermore, when ath-
erosclerotic plaque is detected, its components have already 
been there for about 10 years,161,162 turnover within the lesion 
is slow, and quick improvement or regression in response 
to preventive therapies at that stage should not be routinely 
expected. Lifestyle measures have the advantage of reduc-
ing several risk factors simultaneously whenever they begin. 
Unfortunately, to many people “prevention” evokes images 
of endless, exhausting exercise and intolerable food depriva-
tion, and in part this attitude contributes to the relative poor 
health of Americans.163 Lifestyle therapy is unpopular for 
2 major reasons: (1) it requires time from physicians and 
is nonreimbursable and (2) it requires sustained mental and 
physical effort from patients who want a magic pill for an 
immediate cure, in part so that unhealthy habits may continue. 
Both these obstacles are nonmedical and may be reversed 
with specific, targeted public health policies. In view of the 
above, it is unlikely that without a major population-wide 
effort that includes dietary and other lifestyle changes, as well 
as major social and environmental adjustments, including 
food industry practices, the current progression of obesity, 
diabetes, and CAD will be stopped.164
Traditional risk factors and public health potential
Traditional risk factors include the nonmodifiable: age, 
gender, family history; and the modifiable: use of tobacco, 
hypertension, dyslipidemia, and diabetes mellitus. Obesity 
is not considered in some discussions because effects are 
substantially mediated by its consequences, namely diabe-
tes, hypertension, and dyslipidemia. As a clinical entity, it 
obviously cannot be ignored. Other risk factors of major 
interest include C-reactive protein and chronic renal disease, 
although there are many others.160 In general, there is greater 
value in evaluating and monitoring long-term risk and its 
consequences in vivo rather than short-term risk using sur-
rogates.165 Otherwise, as is now recognized after lowering 
LDL with pharmacological agents, significant residual risk 
will remain unaddressed.
INTERHEART, an international study, showed that 
although 80% of global cardiovascular disease is found in 
nonwealthy countries, the risk factors are the same everywhere 
and apply to men and women of all ages.166 Their striking 
finding was that 9 risk factors accounted for 90% of the risk 
in men and 94% in women. Since all 9 are modifiable, these 
percentages may be construed as possible upper ceilings on Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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the extent to which AMI can be prevented. It is instructive 
to note the population attributable risks and odds ratios for 
various risk factors found to account for AMI in these data 
(Table 6).
In the United States, of 3 risk factors – hypertension, 
diabetes, or dyslipidemia – about 45% of the adult popula-
tion has 1 of them, 13% have 2 of the 3, and 3% has all 3 
diseases. An additional 15% have 1 or more of these condi-
tions that remain undiagnosed.167 To reap maximum benefits 
from following a lifestyle that optimizes risk factor reduction, 
“good behavior” must be applied with sufficient intensity 
to achieve a target reduction in a respective risk factor and 
be consistently maintained over a relatively long period of 
time.168–179 Interestingly, these are the same intensity and 
volume factors described in many physical systems, such as 
thermodynamics. The incubation period of atherosclerosis 
and CAD, according to the Seven Countries Study, is at 
least 10 years.180 Pediatric data, pathological reports from 
the military, and other epidemiological studies suggest the 
typical incubation period may be on the order of 2.0–3.3 ± 
1.8 decades. Under ideal circumstances, lifestyle modifica-
tions should be optimized during this period.181
Remarkably, meaningful improvements may occur much 
sooner when positive changes occur. Patients need to be 
reeducated and understand that transient improvements over a 
few days will not cure, but that life-long changes will produce 
control. Motivating for personal involvement and commit-
ment, emphasizing individual responsibility for health, and 
shifting away from the disease-reactive model of care, add 
another dimension to health delivery and is workable.182 
Pointing out that modest change in health behavior can delay 
aging by 12 years, accompanied by a 25%   reduction in risk 
of death, such as reported by the UK Health and Lifestyle 
Survey183 is powerful material when presented to patients. 
Other advantages of the lifestyle method of management 
include enhanced personal joy, increased productivity, 
and the absence of adverse drug reactions or procedural 
complications.
Primordial prevention to improve  
cardiovascular health
Recently, the AHA has reemphasized the profound potential 
effects of healthier personal habits and behavior patterns 
upon heart disease. The AHA issued a policy statement 
  setting forth structural aspects of effective worksite   wellness 
programs, outlining the benefits of patient education, 
smoking cessation, early detection and screening, weight 
control, nutrition, physical activity, stress management, 
and the environmental and social changes likely to promote 
cardiovascular health.184 Shortly thereafter, the 2010 update 
of heart disease and stroke statistics185 summarized national 
progress and failures with respect to cardiovascular risk 
  factors. High rates of tobacco use, adult and pediatric obesity, 
and hypertension (at 34%) remained significant problems. 
An AHA special report followed,186 defining and setting 
2020 impact goals for   cardiovascular health promotion and 
disease reduction.
This unique document186 combined (1) a needed focus 
on the essence of the public health problem, (2) a blueprint 
and practical plan for the future, (3) a public message, with 
metrics and goals in language the public can easily grasp 
and use, (4) a guide to clinicians, and (5) a summary of the 
evidence-based recommendations. The AHA defined ideal 
cardiovascular health as not only the absence of cardiovas-
cular disease but also following a healthy lifestyle together 
with a normal body mass index (BMI), cholesterol level, 
BP, and fasting glucose without treatment. In this review, 
the concepts discussed above were clearly set forth in the 
context of population-based personal ownership and com-
mitment in affecting habit change. Personal heart-healthy 
Table 6 Relative contributions of risk factors to risk of AMi in the iNTeRHeART studya,166
Risk factor Odds ratio Population attributable risk
Smoking 2.87 (for current vs never) 35.7% (for current and former vs never)
Raised ApoB/ApoA1 ratio 3.25 (for top vs lowest quintile) 49.2% (for top 4 quintiles vs lowest quintile)
History of hypertension 1.91 17.9%
Diabetes 2.37 9.9%
Abdominal obesity 1.12 (for top vs lowest tertile) 
1.62 (for middle vs lowest tertile)
20.1% (for top 2 tertiles vs lowest tertile)
Psychosocial factors 2.67 32.5%
Daily consumption of fruits and vegetables 0.70 13.7% (for lack of daily consumption)
Regular alcohol consumption 0.91 6.7%
Regular physical activity 0.86 12.2%
aAll risk factors were significantly related to AMI (P , 0.0001 for all risk factors and P = 0.03 for alcohol). 
Abbreviation: AMi, acute myocardial infarction.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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lifestyles in a population that did not permit risk factors to 
develop, associated with ideal cardiovascular health, was 
called primordial prevention. This term was coined in 1978 
by Strasser187 to mean intervention that stopped the appear-
ance of risk factors in a population. The same theme was 
featured at the Third International Heart Health Conference 
held in Singapore in1998.
In addition, the 2020 goals statement,186 recognizing the 
early beginnings of risk factors leading to CAD, stressed the 
need for prevention, over years, prior to the development 
of subclinical atherosclerosis and at all levels of risk. The 
  difference between population-wide prevention and individual 
intensive treatment of high-risk patients was made clear.188 
For the first time, optimal health was defined by a venerable 
medical organization as more than the absence of disease, 
and indeed a desirable goal, attainable through lifestyle 
modification. Reversing dyslipidemia and hypertension with 
medications does lower cardiovascular risk, the authors said, 
but does not restore risk to equal the absence of risk enjoyed 
by individuals who never had elevations in the first place. In 
other words, drug-induced reversal of risk factors, although 
necessary and the essential fabric of current therapy, does not 
equal elimination of risk factors through lifestyle, and it is 
in fact excluded from the definition of “ideal cardiovascular 
health”.186 This view not only reflects the pleiotropic action of 
lifestyle elements upon multiple risk factors but also the limi-
tations of risk stratification and treatment, which leave some 
high-risk individuals unidentified and considerable amounts 
of unaddressed residual risk in those who are treated.
The AHA report simplified classification of cardiovas-
cular health in the population into poor, intermediate, or 
ideal depending upon how patients satisfied new criteria, 
consisting of 7 targets:
1.  Never having smoked or quitting over a year ago.
2.  Keeping BMI , 25 kg/m2.
3.  Exercising at moderate intensity $150 minutes (or 
75 minutes at vigorous intensity) each week.
4.  Eating a “healthy diet”: adhering to 4 of 5 important 
dietary components.
a.  sodium intake ,1.5 g/d;
b.  sugar-sweetened beverage intake ,36 oz weekly;
c.  $4.5 cups of fruits and vegetables/d;
d.  $three 1 oz servings of fiber-rich whole grains/d;
e.  $two 3.5 oz servings of oily fish/week.
5.  Maintaining total cholesterol ,200 mg/dL.
6.  Keeping BP , 120/80 mm Hg.
7.  Keep fasting blood glucose ,100 mg/dL.
The 7 targets included specifics regarding intake of 
dietary refined sugar from another closely-timed statement189 
and defined a new limit on salt consumption, relating a 
comparatively small amount of salt to raised risk for cardio-
vascular disease.
Other dietary considerations were not overlooked. The 
importance of minimizing dietary trans and saturated fat, 
avoiding processed foods, especially meats, emphasizing a 
plant-based diet with inclusion of legumes, nuts and seeds, 
raising fiber intake through vegetable sources, and the general 
benefits of the DASH diet were included. The AHA also noted 
that only 5% of Americans presently satisfy these criteria, a 
sobering statistic. Those who do can expect to live 40 addi-
tional years without a cardiac event or stroke.186 Fulfillment 
of the new goals is projected to improve the cardiovascular 
health of Americans $20% by year 2020 and lower AMI 
and stroke deaths by an equal measure. The AHA achieved 
its 2010 goal of lowering heart and stroke deaths earlier 
than expected by a margin of 25%. In the United States, 
mortality from CAD has steadily declined over the past 40 
years;190 hospital morbidity has remained unchanged due to 
age-shifting, and CAD prevalence rose with greater numbers 
of patients diagnosed and surviving. Most recently, hospital-
ization rates for AMI fell 23.4% from 2002–2007 for patients 
over 65 years of age,191,192 although, as discussed above, all 
indicators suggest that rising obesity rates and diabetes may 
handily reverse such gains. Not surprisingly, all contributory 
risk factors found significant in the INTERHEART study 
are included as targets in the AHA criteria, except for psy-
chosocial factors, which   cannot be easily quantified for use 
in this context. Finally, the 7   targets are expressed in simple 
language, without unnecessary   complexities, an essential 
feature for success.
Management of risk factors in patients
In the individual patient with angina, major modifiable risk 
factors need to be addressed and optimized. A 2007 ACC/
AHA Chronic Angina Focused Guideline Update193 revised 
the full 2002 ACC/AHA Chronic Angina Guidelines,5 using 
recent evidence that was considered compelling. Clinicians 
should heed the recommendations made as a basis for treat-
ment (Table 7). Risk reduction in patients with chronic stable 
angina is similar, although certainly not identical to, the risk 
management in primary prevention,194 guidelines written spe-
cifically for women,195 guidelines for secondary prevention 
generally,196 and European guidelines for prevention of heart 
disease.197–200 Related guidelines of interest include those for Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Table 7 Selected recommendations from the ACC/AHA updated guidelines on risk reduction in patients with angina
Risk factor Recommendations COR/LOEa Comments (not part of the guidelines)
Smoking Smoking must be stopped immediately, and second- 
hand smoke should be avoided. Pharmacotherapy  
with nicotine and other approved agents should  
be used along with referral to special programs.  
Use a stepwise strategy:   Ask,   Advise,   Assess,   Assist,  
and Arrange.
i (B) Smoking is a potent and pernicious risk factor.  
Cessation may lower risk by 60% in 3 y, with  
half of that manifested within the first 3–6 months.
Hypertension BP should be kept ,140/90 mmHg,  
or ,130/90 mmHg in DM or CKD.
i (A) evidence at the ACC 2010 sessions raised doubts  
about the wisdom of tight BP control in DM.205,206
Lifestyle modifications: weight control, physical  
activity, low alcohol, sodium intake, high consumption  
of fresh fruits and vegetables and low-fat dairy  
products – an improved “DASH diet” is advised.
i (B) New Joint National Conference 8 Guidelines for 
hypertension are expected late in 2011.
For patients with established CHD, use β blockers  
or ACE inhibitors first, then other agents.
i (C) when a prior AMi has not occurred, ACe/ARB  
use is quite discretionary – see below.
Dyslipidemia when baseline LDL $ 100 mg/dL, begin drugs  
with lifestyle measures.
i (A) intensify therapy to reach 30%–40% reduction  
in high-risk patients, or ,70 mg/dL.
Daily exercise, weight control, low-saturated fat  
diet ,7%, reduce dietary TFA, and cholesterol 
intake ,200 mg/d.
i (B) The less dietary TFA, the better.
if TG = 200–499 mg/dL, non-HDL should  
be ,130 mg/dL.
Add plant stanols 2 g/d and/or soluble fiber .10 g/d. iia (A) A somewhat greater intake may improve results,  
with maximum reduction of about 9% from each 
maneuver.
Lowering LDL , 70 mg/dL or using high-dose  
statins is reasonable.
iia (A) Aggressive LDL lowering is being favored in 
many different clinical situations, but still leaves 
unacceptable residual risk.
if baseline LDL is 70–100 mg/dL, lowering LDL  
to , 70 mg/dL is reasonable.
iia (B)
when TG are 200–499 mg/dL, lowering  
non-HDL , 100 mg/dL is reasonable.
iia (B) Although LDL remains the official primary target, 
non-HDL better incorporates the atherogenicity  
of other particles.
Niacin or fibrates can be used to lower  
non-HDL after LDL therapy is begun.
iia (B)
Omega-3 fish oil, 1 g/d is reasonable. Greater  
amounts (.2.5/d) are needed for elevated TG levels.
iib (B) 1g fish oil means the sum of EPA + DHA, not 
total marine oil. Most people consume too little, 
even from supplements. More usually offers better 
protection against SCD. Omega-3 fats are pleiotropic.
TG . 500 mg/dL should be addressed first to avoid  
pancreatitis with fibrates or niacin.
i (C)
weight control Keep BMi between 18.5–24.0 kg/m2. Aim for  
a 10% reduction first. Be persistent and measure  
waist circumference. if it is $40" (102 cm) in men  
or 35" (89 cm) in women, consider MetS, especially  
in men with waists 37–40" (94–102 cm) with  
genetic insulin resistance.
i (B) Sustained weight control, since there is no truly 
effective pharmacologic therapy, is most difficult to 
achieve without surgery, but it is fundamental to risk 
reduction.
Physical activity Recommend 30–60 min of moderate-intensity aerobic 
activity, 7 d/wk, a minimum of 5 d/wk, supplemented  
by an increase in daily activities. An activity history  
should be recorded, and an exercise test is  
performed to guide the exercise prescription.  
CR programs should be recommended  
for at-risk patients such as recent ACS  
or revascularization, or HF.
i (B)
Resistance training 2 d/wk may be reasonable. iib (C) 3 days of strength training 45–60 min each session  
is usually the eventual goal if medically appropriate.
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unstable angina/NSTEMI,173,201,202 exercise testing203 and the 
ACC/AHA/SCAI updates on PCI.204
Revascularization
Revascularization is a mechanical treatment for flow-limiting 
coronary obstructive lesions in order to relieve myocardial 
ischemia. In 2006, about 1,313,000 PCI procedures and 
448,000 CABG surgeries were performed in the United 
States.185 Many cardiologists, surgeons, and indeed, patients 
believe that for angina and ACS, revascularization with PCI 
or CABG – when appropriate – are the preferred treatments. 
There is little question that in high-risk ACS patients a routine 
invasive strategy produces the best outcomes, but thresholds 
have been unclear for some patients with chronic angina. 
About 85% of the PCIs performed are elective,209 25% are in 
patients with chronic stable angina, and approximately half 
are in patients above 65 years of age.210 Although no hard 
data are available, estimates of those who are asymptomatic 
range from 12% to 25%. In 2004, only 44% of elderly patients 
underwent a noninvasive study prior to referral for PCI, cur-
rently part of evidence-based guidelines.211
PCi
The ACC/AHA guidelines for managing patients with 
chronic stable angina recommend PCI in high-risk patients 
as determined by noninvasive testing or for patients in whom 
Table 7 (Continued)
Risk factor Recommendations COR/LOEa Comments (not part of the guidelines)
Diabetes Keep HbA1c levels “near normal”. i (B) ACCORD and other studies have recently modified 
views on the merits of very tight control.39,207,208 
HbA1c guidelines from the ADA remain intact 
presently.
Reduction of other risk factors (weight, physical  
activity, dyslipidemia, and BP should be vigorously 
pursued as recommended).
β blockers Begin and continue indefinitely in all patients  
with prior AMi, ACS, or LV dysfunction with  
or without HF symptoms unless contraindicated.
i (A) See discussion above concerning β blockers.
Antiplatelet  
agents
72–162 mg aspirin should be used in all patients  
and be continued indefinitely unless contraindicated.
i (A) Use in primary prevention is controversial.
Use with warfarin, and clopidogrel may  
increase bleeding and should be monitored.
i (B) Genetic variation in responsiveness is now of clinical 
importance. Use of PPis with clopidogrel is debated, 
and there is an FDA warning.
RAA system 
blockers
ACei should be used in all patients with LVeF # 40%  
in all patients and in those with HTN, DM, or CKD.
i (A)
ARB should be used for those with HTN with  
indications but who cannot tolerate ACei, have HF,  
or are post-Mi with LVeF # 40%.
Aldosterone blockers should be used in post-Mi  
patients without creatinine .2.5 mg/dL in men,  
.2 mg/dL in women, or K+ . 5 meq/L, who are  
receiving adequate doses of an ACei and a β-blocker,  
have LVeF # 40%, and have either DM or HF.
ACei for patients who are not low risk, ie, normal  
LVeF and in whom risk factors are controlled and  
revascularization has been performed.
i (B) For patients who have not sustained an AMi, use of 
ACei or ARB in angina patients is not established.
Vaccination Influenza vaccination-recommended annually. i (B)
Notes: There are 5 treatments that are considered class I (A), ie, should be done in all patients. There are no lifestyle recommendations that are I (A), and specific diet 
changes are not addressed. Currently available data concerning diet and lifestyle do not permit such classifications, but are potent therapies.
aCOR, classifications of recommendations is as follows: class I, benefit ... risk, and treatment should be done; class IIa, benefit .. risk, and it is reasonable; class iib, 
benefit $ risk, and it may be considered; class iii, risk $ benefit, and the treatment should not be done since it is not helpful and may harm. Class III items have been 
omitted. LOe, level of evidence, an estimate of certainty of treatment effect, is as follows: level A, useful in different subpopulations, with general consistency of direction and 
magnitude of effect; level B, only 2 to 3 subpopulations or risk strata have been evaluated; level C, limited, with 1 to 2 subpopulations evaluated. Classification as levels B or 
C does not imply ineffectiveness or weakness of the recommendation, simply that clinical trials have not been performed.
Abbreviations: ACC, American College of Cardiology; AHA, American Heart Association; COR, classifications of recommendations; LOE, level of evidence; BP, blood 
pressure; DM, diabetes mellitus; CKD, chronic renal disease; CHD, coronary heart disease; ACe, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; LDL, 
low-density lipoprotein; TFA, trans fatty acids; TG, triglycerides; HDL, high-density lipoprotein; BMi, body mass index; SCD, sudden cardiac death; CR, supervised cardiac 
rehabilitation programs; ACS, acute coronary syndrome; HF, heart failure; ADA, American Diabetes Association; AMi, acute myocardial infarction; PPis, proton pump 
inhibitors; FDA, Food and Drug Administration; RAA, renin-angiotensin-aldosterone; ACei, angiotensin-converting enzyme inhibitor; LVeF, left ventricular ejection fraction; 
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optimal medical treatment has failed.4 Accordingly, there are 
essentially 2 indications: either for relief of pain and disability 
or to prolong or save lives (Table 8).
Although several small trials prior to 2004 did confirm 
that PCI improved chest pain frequency and short-term 
exercise tolerance in patients with chronic angina, they 
failed to show that PCI either improved survival or prevented 
subsequent MI. In addition, there was significant persistence 
of angina and only minor reduction in the number of anti-
anginal medications after the procedure. A meta-analysis of 
11 randomized studies involving 2,950 patients with stable 
CAD treated with PCI showed no improvement in mortal-
ity, MI, or need for further revascularization, compared with 
medical management.212
The COURAGE trial compared outcomes in patients 
with chronic angina treated with PCI together with optimal 
medical therapy (OMT), the PCI group, and patients treated 
with OMT alone, the OMT group.213 The primary outcome 
was all-cause mortality or nonfatal MI during a follow-up 
period of 2.5–7.0 years (median, 4.6 years). The study 
enrolled 2,287 patients with entry criteria of (1) stenosis 
of at least 70% in at least 1 proximal epicardial coronary 
artery, and objective evidence of myocardial ischemia 
(substantial changes in ST-segment depression or T-wave 
inversion on the resting ECG or inducible ischemia with 
either exercise or pharmacologic vasodilator stress) or (2) at 
least 1 coronary stenosis of at least 80% and classic angina 
without provocative testing. Exclusion criteria included an 
overtly positive stress test, CCS class IV angina, refractory 
HF or EF , 30%, revascularization within the prior 6 months, 
or coronary anatomy that precluded successful PCI. Patients 
who underwent PCI received aspirin and clopidogrel. Medi-
cal therapy consisted of long-acting metoprolol, isosorbide 
mononitrate, and amlodipine in various combinations, with 
either losartan or lisinopril for secondary prevention. Therapy 
to lower LDL to 60–85 mg/dL (1.55–2.20 mmol/L) with sim-
vastatin and/or ezetimibe was followed by attempts to raise 
HDL . 40 mg/dL (1.03 mmol/L) and lower TG , 150 mg/dL 
(1.69 mmol/L) with exercise, niacin, and/or fibrates. Finally, 
in patients undergoing PCI, the goals were primary lesion 
revascularization, then total revascularization if possible. 
Angiographic success was defined as normal coronary blood 
flow and ,50% stenosis in the luminal diameter after bal-
loon angioplasty and ,20% after stent implantation. Clinical 
success was angiographic success plus the absence of an 
in-hospital MI, emergency CABG, or death.
The study found that the PCI group and the OMT group 
did not differ significantly as far as the composite end point 
of death, MI, stroke, and hospitalization for ACS or for MI. 
Mortality for the 2 groups were 7.6% and 8.3%, respectively. 
Additional revascularization for angina refractory to OMT or 
for worsening ischemia on noninvasive testing was necessary 
in 21.1% of patients in the PCI group and in 32.6% in the 
OMT group. In other words, about one-third of the OMT 
group crossed over. Moreover, in subgroups with multives-
sel disease (67% of patients), with previous MI or diabetes, 
the primary end point was no different between treatment 
groups. Although there was an increase in angina-free status 
in patients undergoing PCI at 1 and 3 years, at 4.6 years the 
percentage of angina-free patients was 74% in the PCI group 
and 72% in the OMT group. In summary, the COURAGE trial 
found that PCI with OMT was not superior to OMT alone 
in preventing MI or death in symptomatic or asymptomatic 
patients with chronic angina and similar inclusion and exclu-
sion criteria. In patients who have left main coronary artery 
lesions, who are unstable, or in whom OMT has failed, PCI 
would of course be preferred.
Limitations in COURAGE trial include a preponderance 
of men (85%) and insufficient numbers of patients with EFs 
between 30% and 50%. Since drug-eluting stents (DES) were 
unapproved until the final 6 months of the study, most stents 
were bare-metal (BMS). DES might have lowered the rate 
of repeat revascularization, which is found in about 25% of 
BMS placements. At the same time, however, use of DES 
would have introduced the possibility of associated late stent 
thromboses,214–216 although now of less concern than when 
the issue was initially evaluated.217–219
It should be noted that ranolazine was not used in the 
COURAGE trial as part of the anti-ischemic protocol. In 
the MERLIN-TIMI 36 trial discussed above, a number of 
patients enrolled had chronic angina resembling those in the 
Table 8 ACC/AHA recommendations for PCi in patients with 
chronic stable angina4
Recommendations Class I 
LOE
2-vessel or 3-vessel disease with significant proximal LAD  
lesions, with anatomy enabling catheter-based therapy  
and normal LVF; diabetics under treatment excluded.
i (B)
1-vessel or 2-vessel disease without significant proximal  
LAD lesions, with high risk on noninvasive testing and a  
large area of viable myocardium.
i (B)
Prior PCi with either recurrence of stenosis or high risk  
on noninvasive testing.
i (C)
Failure of optimum medical therapy and with acceptable  
risk for revascularization procedure.
i (B)
Abbreviations:  ACC/AHA,  American  College  of  Cardiology/American  Heart 
Association; PCi, percutaneous coronary intervention; LOe, level of evidence; LAD, 
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COURAGE trial.102,103 Based upon MERLIN-TIMI 36 trial, 
it is likely that ranolazine not only has a place in OMT for 
stable angina but also possibly for chest pain associated with 
ACS as well.220 Just as ranolazine does not change the natural 
history of chronic stable angina, it does not prevent MI or 
death in ACS. In the COURAGE study, a subset of patients 
continued to have angina despite OMT with PCI. Similarly, 
a number of patients experienced angina 1 year after PCI or 
CABG,221 indicating a need for additional therapies.
Although the COURAGE trial was regarded as practice-
changing and a basis for recommending OMT as initial 
therapy for stable angina, the greater significance of the 
findings are that lifestyle changes and OMT have been under-
estimated and are more powerful than previously believed. 
The COURAGE trial also indicates that in stable patients, 
deferring intervention while under OMT is a viable approach, 
which does not significantly raise risk. Further, COURAGE 
data are consistent with current views about the pathogenesis 
of stable angina and ACS (see part I of these articles1 for a 
brief discussion of the pathology).
CAD is a diffuse disease, and OMT is a systemic therapy 
to prevent widespread atherosclerosis, and, when aggressive, 
is believed to stabilize plaques wherever they are. When fixed 
obstructive lesions can be visualized in epicardial vessels and 
coronary flow is restored, angina may be relieved. In   contrast, 
ACS is caused by coronary thrombosis resulting from   rupture 
of unstable, vulnerable plaque with thin fibrous caps, espe-
cially ,65 µm, infiltrated by macrophages, with large necrotic 
cores, containing relatively less collagen matrix and smooth 
muscle. Not prone to expand toward the lumen, they are 
generally nonflow-limiting, and pathologically, may occur at 
areas other than significant stenoses, in lesions that may not 
be visualized on angiography. In fact, some data show risk 
for MI is unrelated to severity of stenoses. Therefore, open-
ing discrete stenoses using PCI, a focal rather than diffuse 
therapy, would not be expected to affect vulnerable plaques 
that might rupture and cause future MI or deadly events. PCI 
adequately clears amenable fixed coronary obstructions but 
does not lower the burden of diffuse histological coronary 
atherosclerosis or the molecular pathogenesis. Reciprocally, 
aggressive lipid lowering with statins is more effective in 
reducing cardiac events than it is in causing regression of 
tight stenoses.222 Presently, it is not clinically possible to 
reliably locate or predict rupture in   vulnerable plaques. Obvi-
ously, there is much to be learned.
An editorial accompanying COURAGE223 noted that the 
overall 4.6-year rate of MI was about 19% and mortality 
was 8% in both study groups. The 2.8% periprocedural MI 
was higher than anticipated, but included patients with prior 
PCI and multiple lesions that were dilated. In general, PCI 
is associated with a 1.27% risk of mortality, ranging from 
0.65% in elective PCI to 4.81% in STEMI patients,224 about 
2%–5% periprocedural MI, and ,1% emergent CABG for 
a complication.
Post-COURAGE analysis suggested that adding PCI to 
OMT would not be cost-effective.225 A QoL analysis found that 
the improvement in QoL from adding PCI to OMT was too 
small to be clinically important and that PCI was not always 
necessary for the relief of symptoms.226 An   additional specified 
subset analysis of COURAGE confirmed the original findings 
in the elderly.227 Other commentaries followed with supporters 
and opponents about the validity of the   COURAGE trial.228–231 
Is it realistic that a patient with angina and 80% obstruction 
in 2 of 3 coronary arteries be medically treated rather than 
stented? A nuclear-imaging substudy using SPECT suggested 
that patients with moderate to severe ischemia benefited more 
through PCI than OMT.228 Design flaws, use of BMS rather 
than DES, suboptimal PCI, and unrealistically good medical 
care not representative of actual patient services were also 
cited in the failure of PCI to outperform OMT.231 A release of 
the details in COURAGE revealed the extraordinary efficiency 
and aggressive nurse case management used, with most medi-
cations supplied without cost.232 Organization, function, and 
funding of most medical practices are simply not able to deliver 
the intensity of medical therapy afforded to the participants 
in   the COURAGE trial. For this reason, the reproducibility of 
COURAGE results in the general population is unknown.233 
Preventive care only works if it is done, and adherence to 
multiple drugs, lifestyle changes, and scheduled tests, given 
the documented poor history of patients thus far with respect 
to risk reduction pharmacy and behavioral improvements, are 
an unrealistic expectation.
In the midst of a strong defense of the COURAGE 
trial, there has been mention of excessive numbers of PCI 
procedures that may not be evidence-based.229 It is estimated 
that   one-third of PCIs now performed would be COURAGE-
eligible to forego the procedure and follow OMT.230 If this 
occurred, great attention to adherence to OMT would be 
necessary, using a case management system similar to the 
one used in the COURAGE trial.232 Issuing prescriptions 
using the current paradigm of patient care would be 
insufficient. Care management systems are feasible and 
effective when used with high-risk cardiovascular patients. 
They improve health behaviors and adherence to prescribed 
medications and monitoring, with projected lower rates of 
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A meta-analysis of 17 randomized trials comparing PCI 
and medical therapy in patients with angina but not ACS 
found a 20% reduction in odds ratio for all-cause death in a 
PCI group,235 prompting a call for a new clinical trial with 
greater power than COURAGE, but simultaneously recom-
mending more aggressive medical therapy for patients with 
chronic angina.236
In summary, OMT and PCI are complementary therapies 
with somewhat overlapping but specific indications, which 
are not mutually exclusive.
CAD epicardial lesion burden, prognosis, 
and COURAGe
Some authors reason that since ischemia – obstructive lesions 
as detected by perfusion imaging237,238 – worsens prognosis, the 
extent of stenosis may correlate with mortality,239 and revas-
cularization through PCI or CABG increases survival,240 then 
PCI should be more effective in trials such as COURAGE.241 
A relatively short follow-up in relation to the long incubation 
period and slow regression of atherosclerosis, limited numbers 
of patients in studies, and unnecessarily complex PCI tech-
niques are cited as possible causes of the disparity.241
Indeed, cardiac risk and prognosis of patients with CAD 
are generally related to the burden of atherosclerosis as it is 
customarily tallied.5 The survival rates of patients with CAD 
(Table 9) follow both severity and location of lesions.242 In 
the years since these data were gathered, medical therapy has 
advanced significantly and is reflected in improved survival, 
but the relationship between severity of obstructions and 
prognosis remains valid.243,244
CABG
Classic recommendations for CABG surgery include patients 
with left main coronary lesions, symptomatic 3-vessel dis-
ease, critical (.75%) stenoses in all 3 major coronary arteries 
and LVEF , 50%, diabetics with multivessel disease, and 
very complex lesions. Generally, CABG produces lower 
rates of repeat revascularization and longer survival times 
than PCI. The risks of CABG surgery include 1%–3% death, 
5%–10% perioperative MI, 10%–20% vein graft failure 
(first year), and a low risk of perioperative stroke and cogni-
tive dysfunction. About 75% of patients remain angina-free 
or free of cardiac events after 5 years. Selected guidelines 
for revascularization are summarized in Table 10.
How well do catheterization cardiologists follow ACC/
AHA guidelines when recommending PCI or CABG? About 
94% of patients in whom PCI was indicated (according 
to the guidelines) were recommended for PCI, but 93% 
of the patients who satisfied indications for either PCI or 
CABG were recommended for PCI.245 In those for whom 
the guidelines recommend CABG, 53% were recommended 
for CABG, and 34% were recommended for PCI. Finally, in 
patients for whom neither PCI nor CABG were indicated, 
21% were recommended for PCI.
As a supplement to guidelines, appropriateness criteria 
for coronary revascularization were issued to help guide 
Table 9 extent of CAD in nonresistance vessels, 5-year survival 
rate  (%),  and  prognostic  weight  (0–100),  based  upon  medical 
therapy only242
Extent of CAD 5-year  
survival  
(%)
Prognostic   
weight  
(0–100)
1-vessel disease, 75% 93 23
.1-vessel disease, 50%–74% 93 23
1-vessel disease, $95% 91 32
2-vessel disease 88 37
2-vessel disease, both $95% 86 42
1-vessel disease, $95% proximal LAD 83 48
2-vessel disease, $95% LAD 83 48
2-vessel disease, $95% proximal LAD 79 56
3-vessel disease 79 56
3-vessel disease, $95% in at least 1 73 63
3-vessel disease, 75% proximal LAD 67 67
3-vessel disease, $95% proximal LAD 59 74
Abbreviations: CAD, coronary artery disease; LAD, Left anterior descending.
Table 10 Selected ACC/AHA guidelines for revascularization 
with CABG5
Recommendations for CABG Class and level 
of evidence
Significant left main coronary disease. i (A)
Triple-vessel disease; survival benefit is greater  
in patients with LVeF , 50%.
i (A)
Double-vessel disease with significant proximal  
LAD disease and either LVeF , 50% or  
demonstrable ischemic on noninvasive testing.
i (A)
1- or 2-vessel disease without significant proximal  
LAD lesions, with high risk on noninvasive testing  
and a large area of viable myocardium.
i (B)
1- or 2-vessel disease without significant proximal  
LAD lesions who have survived SCD or sustained VT.
i (C)
Failure of optimum medical therapy and with 
acceptable risk for a  revascularization procedure.
i (B)
1- or 2-vessel disease without significant proximal  
LAD Lesions, but with a moderate area of viable  
myocardium and demonstrable ischemia on  
noninvasive testing.
iia (B)
Single vessel disease with significant proximal  
LAD disease.
iia (B)
Abbreviations:  ACC/AHA,  American  College  of  Cardiology/American  Heart 
Association; CABG, coronary artery bypass surgery; LAD, Left anterior descending; 
LVeF, left ventricular ejection fraction; SCD, sudden cardiac death; VT, ventricular 
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clinicians with input from 6 medical societies.246 The 
appropriateness criteria drew from at least 5 individual 
guidelines concerning imaging, exercise testing, and specific 
therapies, but it also blended the experience of experts into 
the text. The technical panel composed of cardiologists, 
surgeons, interventionalists, radiologists, internists, and 
health-services researchers rated some 180 clinical scenarios 
for appropriateness in performing revascularization in this 
project. Most of the categories considered appropriate 
are listed in Tables 8 and 10. Other noteworthy reviews 
concerning effectiveness of PCI and CABG for CAD include 
one by the Agency for Healthcare Research and Quality247 
and a recent narrative.248
Conclusion
Advances in the understanding of ischemic heart disease and 
improved technology during the last decade have been strik-
ing. These have occurred in the areas of epidemiology, risk 
assessment, pharmacological risk factor reduction, mecha-
nisms of disease, early detection, imaging, interventional 
cardiology, electrophysiology and devices, and surgery.
Cardiovascular disease is the leading cause of death in 
the United States, yet it is a preventable disease. The current 
epidemic of obesity threatens to reverse recent advances 
in controlling this foe. For this reason, bold proposals and 
calls for implementation of population-wide lifestyle and 
environmental changes are being made.
In the individual patient, the clinician has a broader spec-
trum of potent tools than ever before at his or her disposal 
to prevent and manage chronic stable angina. Applied in an 
evidence-based manner, current therapies permit patients to 
live pain-free, participate in physical and social activities, 
and enjoy a fuller, longer life.
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